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Abstract 
In livestock production corticosteroids are licensed only for therapy, nevertheless they are 
often illegally used as growth promoters. The aim of this study was to identify morphological or 
biomolecular alterations induced by prednisolone (PDN) in experimentally treated beef cattle, since 
PDN and its metabolites are no longer detectable by LC-MS/MS methods in biological fluids. 
Moreover, PDN do not induce any histological alterations in thymus, differently from 
Dexamethasone treatments. Therefore, a marker of illicit treatment for this growth promoter could 
be useful. Eight male Italian Friesian beef cattle were administered prednisolone acetate 30 mg 
day
−1
 per os for 35 days, while seven beef cattle represented the control group. Six days after drug 
withdrawal the animals were slaughtered. Morphological and morphometric modifications were 
evaluated in epididymis and testis, whereas transcriptomic changes induced by PDN administration 
were investigated in Peripheral Blood Mononuclear Cells (PBMCs) at different sampling times, and 
in skeletal muscle and testis sampled at slaughtering. In the epididymis, spermatozoa number 
decreased in PDN treated animals, and in some cases they were totally absent. Correspondently, in 
testis of treated animals, down-regulation for serine/threonine kinase 11 (STK11) gene expression 
was detected (p<0.01). DNA microarray analysis revealed a total of 133 differentially expressed 
genes in skeletal muscle and testis, and 907 and 1,416 in PBMCs after 33 days of treatment and at 
slaughtering, respectively. Histological investigations on epididymal content could represent a 
promising marker for PDN treatment in beef cattle, and could be used as a screening method in 
order to identify animals worthy of further investigation with official methods. Moreover, the clear 
transcriptomic signature of PDN treatment evidenced in PBMCs supported for the possibility of 
using this matrix to monitor the illicit treatment in vivo during ranching. 
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Introduction 
Dexamethasone (DEX) and prednisolone (PDN) are corticosteroids (CSs) frequently used in 
livestock production. They are licensed for therapy in human and veterinary medicine due to their 
anti-inflammatory and immunosuppressive properties
1
. Moreover, CSs are often illegally used as 
growth promoters in animal husbandry, usually at low dosages and by oral administration, either 
alone or in cocktails containing different anabolic agents
2
. To protect consumer’s health, European 
Union established maximum residue limits for these CSs in several biological matrices, such as 
muscle, kidney, liver and milk from different species
3
. Since 2008, the Italian National Program for 
Residue Surveillance (PNR) has detected a marked increase of cattle positive for CS treatments, 
including PDN
4
. Due to the rapid metabolism and excretion of PDN, the analyses of its residues by 
LC/MS-MS are not suitable. The Italian Ministry of Health introduced thymus histological 
examination as a screening test
5
, in order to identify DEX illegal treatments in cattle, since DEX 
induces thymus atrophy 
6-10
. Unfortunately, PDN illegal treatments does not induce thymus 
morphological alterations in beef cattle
11
; moreover, gene expression profiling by DNA-microarray 
on thymus has revealed to be a weak tool to detect the illegal use of PDN
12
. Consequently, new 
reliable tests would be helpful to reveal PDN abuse in livestock production. 
The aim of this study was to recognize alterations induced by PDN treatment in other 
biological matrices. Morphological and morphometric modifications were evaluated in epididymis 
and testis, whereas transcriptomic signatures of PDN administration were investigated in Peripheral 
Blood Mononuclear Cells (PBMCs), skeletal muscle (Biceps brachii) and testis collected from 
experimentally treated beef cattle, in order to identify and recognize potential biomarkers to be used 
for screening purposes. 
 
Material and methods 
Animals and Experimental Design  
Experimental design was already described in details by Cannizzo et al.
12
. Briefly, fifteen 
male Italian Friesian beef cattle (9-17 month-old) were randomly assigned to two groups: group P 
(n = 8) was administered prednisolone acetate (PA, Novosterol, Italy) 30 mg day
−1
 per os for 35 
days, from day 51 to day 85, while group K (n = 7) represented the control group. Six days after 
drug withdrawal the animals were slaughtered. The experiment was authorized by the Italian 
Ministry of Health and the Ethics Committee of the University of Turin and the carcasses of the 
treated beef cattle were appropriately destroyed
13
.  
Animals were weighed before first treatment and the day before slaughtering and weight 
gain was recorded, as reported in Cannizzo et al.
12
. Relative testis weight was calculated as testis 
weight (g)/animal weight (kg) ratio. 
 
PBMCs isolation  
Blood samples were collected from each animal with evacuating tubes containing acid-
citrate-dextrose (ACD) as anticoagulant from the external jugular vein at 0 (T0), 51 (T1), 61 (T2), 
84 (T3), and 92 (T4) days (Fig. 1). The PBMCs were isolated on Ficoll-gradient as previously 
described
14
. PBMCs were pelleted by centrifugation, and resuspended in RNAlater® (Thermo 
Fisher Scientific, MA, USA). Pellet was frozen in TRIzol Reagent (Thermo Fisher Scientific) at 
−80°C until RNA extraction. 
 
Post mortem tissue sampling and processing  
At slaughtering, samples from Biceps brachii muscle, testis and caudal epididymis were 
collected from each animal and opportunely stored for subsequent investigations. For histological 
analysis testicular and epididymal tissues were immediately fixed in Bouin-Hollande solution for 
approximately 24 h, then dehydrated in ethanol, paraffin embedded, and sectioned at 4 µm. 
Haematoxylin and eosin (HE) stained sections were observed under a light microscope, and 
submitted to morphometric analysis and immunohistochemistry for Ki67. Samples from testis and 
epididymis were also glutaraldehyde fixed and ultrastructural features were examined by 
transmission electron microscopy (TEM). For TEM analysis the samples were cut into small pieces 
(2x2 mm), fixed in 2.5% glutaraldheyde (TAAB, England) at 4°C in PBS pH 7.4 for 2 h, and post 
fixed in 1% tetraoxide osmium (OsO3) (Next Chimica, South Africa) at 4°C in PBS for 2 h. The 
tissues were then dehydrated through ascending grades of ethanol, incubated in propylene oxide 
(TAAB) at room temperature for 5 min and embedded in Epon 812 (TAAB). Resin blocks were 
solidified at 60°C for 48 h. Semithin sections (1 µm) were cut and stained with 1% toluidine blue 
(w/v) pH 3.5. Silver coloured ultrathin sections (60-70 nm) were collected onto copper grids coated 
with a Formvar layer (EMS, PA, USA) and double stained with uranyl acetate and lead citrate. 
Microphotographs were obtained at 80 kV on a CM12 STEM electron microscope (Philips).  
For gene expression analysis a portion of skeletal muscle and testis (approximately 100 mg) 
was immediately fixed in RNAlater
®
 and stored at -80°C. 
 
Morphometric Analysis  
Morphometric analyses on testis and epididymis samples were performed on HE stained 
sections. Digital microphotographs were obtained with a Nikon DS-Fi1 color digital camera (Nikon 
Instruments, Italy), at 200x magnification for testis and at 600x for epididymis under a light 
microscope. For testis, at least 40 randomly selected complete tubules per animal were examined 
using Image-Pro Plus software (Media Cybernetics, MD, USA). Seminiferous tubular equivalent 
diameter (STED), seminiferous epithelial height (SHE), area occupied by the seminiferous tubules 
and interstitial area were evaluated. Furthermore, the number of Sertoli cells, spermatogonia, 
spermatocytes, immature and mature spermatids and immature spermatozoa (ready to be released) 
present in at least 30 tubules for each animal were annotated, analyzing sections at 400x 
magnification. For epididymis, at least 25 randomly selected ducts per animal were examined and 
the epithelial height was recorded. 
 
Evaluation and quantification of cell proliferation 
Immunohistochemical staining for Ki67 antigen was performed to evaluate proliferating 
cells on testis sections. Endogenous peroxidases were inactivated and antigen retrieval was 
performed with citrate buffer 10 mM, pH 6.0 at 98°C for 40 min in a water bath. The sections were 
subsequently incubated at room temperature with anti-Ki67 monoclonal antibody (1:50 in PBS) 
(clone MIB-1, Dako, Italy) for 90 min. The staining was visualized with the Dako REAL EnVision 
Detection System (K5007, Dako, Italy) by a Dako Autostainer (Dako). Ten randomly selected fields 
for each section were analyzed, after taking microphotographs at 200x magnification by light 
microscopy, using Image-Pro Plus software. The area of Ki67-positive nuclei was recorded and 
expressed as a percentage (mean ± sd). 
 
Detection of apoptosis in testis 
From each animal 4 μm thick sections of testis were stained using the ApopTag In Situ 
Apoptosis Detection Kit (Merck Millipore, MA, USA) according to the manufacturer’s instructions. 
The immunohistochemical TUNEL (terminal uridine deoxynucleotidyl transferase dUTP nick-end 
labeling) staining was used to reveal the apoptotic nuclei, counterstaining the reaction with methyl 
green 0.5 per cent (w:v) for 10 minutes, and destaining in n-butanol.  
 
RNA extraction  
Samples of testis, skeletal muscle and PBMCs were treated with TRIzol Reagent 
(Ambion®, Thermo Fisher Scientific) and, in order to remove DNA contamination, the extracted 
RNA was subjected to DNAse digestion with the QIAGEN RNase-Free DNase Set (Qiagen, 
Germany). RNA purification was performed with the RNeasy MinElute Cleanup Kit (Qiagen, 
Germany). The concentration of RNA samples was determined by a UV-Vis spectrophotometer 
NanoDrop ND-1000 (Nanodrop Technologies, DE, USA) and RNA integrity was checked using an 
Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). Only RNA samples with RNA 
integrity number (RIN) ≥ 7.0 were included in the analysis. 
 
Relative quantification of STK11 by qPCR 
cDNA was synthesized from 1 μg of total RNA using the QuantiTect Reverse Transcription 
Kit (Qiagen, Germany). The relative amounts of specific Bos taurus serine/threonine kinase 11 
(STK11) mRNA (XM_003586293) was calculated submitting the cDNA to qPCR
15
 with an IQ5 
detection system (BioRad) using IQ SYBR Green Supermix (BioRad, CA, USA). Primer sequences 
of STK11 were designed using Primer 3 (vers. 0.4.0)
16
 (forward: GACAGTGATGCCCTACCTGG, 
reverse: GGCACTGTGAAGTCCTGAGT, amplicon size 108 bp). The peptidylprolyl isomerase A 
(PPIA) gene was used as a housekeeping gene control as previously reported
17
.  
After confirming that target and housekeeping gene amplifications had similar efficiencies, 
gene expression levels were determined using a relative quantification assay, using the comparative 
Cq method (Cq method)18. Then, the relative abundances of each transcript were calculated as 2-
Cq
 (fold increase)
19-21
, normalised to PPIA and relative to the control sample. 
 
RNA amplification, labeling and hybridization  
Sample labeling and hybridization were performed according to the Agilent One-Color 
Microarray-Based Gene Expression Analysis protocol, as reported in details in Pegolo et al. (2012). 
Briefly, 200 ng of total RNA were linearly amplified for each sample and labeled with Cy3-dCTP. 
Microarray data have been deposited in NCBI's Gene Expression Omnibus
22
 (GSE50037, GEO 
Series accession number). 
 
Normalization of microarray data 
Microarray data extraction was performed using the standard procedures of the Agilent 
Feature Extraction Software version 9.5.1. On the basis of the uniformity of the Spike-in intensities 
across the samples, all samples (negative and treated samples) were normalized together in a single 
run using the cyclic LOWESS (Locally-weighted Regression) normalization procedure. 
After normalization, an additional quality control step was introduced to remove probes with  
intensity values lower than the second lowest spike-in concentration in the 70% of samples, as this 
value was considered too close to the limit of detection. The cut-off intensity values corresponded 
to 3.5 for muscle and testis samples and to 4 for PBMCs samples. This filtering step resulted in the 
removal of 1,350, 4,162 and 4,318 unique transcripts for testis, muscle and PBMCs, respectively. 
Filtering and normalization procedures were performed using R statistical software, 
available at http://www.r-project.org/. 
 
Statistical analyses  
t-test or the non parametric Mann-Whitney Test were performed using GraphPad InStat 
(vers. 3.05) statistical software (GraphPad, CA, USA). The Grubbs test was used to exclude 
potential outliers. A p value of <0.05 was considered to be statistically significant. 
Differential expression of microarray data was tested by t-test statistics using TMEV suite
23
 
and the differentially regulated genes (DEG) were identified on the basis of a false discovery rate 
(FDR) <0.05 and a fold change (FC) >1.5. Sample class prediction was implemented using the 
program PAM
24
, available online at http://www.stat.stanford.edu/~tibs/PAM.  
 
Functional enrichment analysis 
The Functional Annotation tool available in the DAVID Database 
(http://david.abcc.ncifcrf.gov/) was adopted to carry out the enrichment analysis on the 
differentially up- and down-regulated genes. All GO terms and KEGG (Kyoto Encyclopedia of 
Genes and Genomes) pathways included in the DAVID knowledgebase were included. For KEGG 
terms, GO Biological Process (BP_FAT) and Molecular Function (MF_FAT), the following 
parameters were selected: gene count 4, ease 0.05.  
 Results 
Animal welfare and livestock performances 
As already reported by Cannizzo et al.
12
, when compared to the control group, weight gains 
were larger in group treated with PDN (p = 0.0047), indicating that the animals responded to PDN 
administration. Also, the average daily gain was higher in group P, compared to group K (1.587 vs. 
1.178 kg/day; P = 0.007), whereas relative testis weight did not vary between treated animals and 
controls (0.583±0.117 vs. 0.606±0.051 g/kg).  
 
Testis morphological features 
Morphological and ultrastructural analyses of testis showed a wide heterogeneity of tubular 
epithelium appearance in animals belonging to group P. The interstitium did not show significant 
alterations. Lesions were totally absent in three cases, whereas they heavily characterized the other 
treated animals. Two cases showed an apparently reduced SHE, whereas in other animals the germ 
line appeared complete. Both light microscopy and TEM revealed in group P a prominent 
vacuolization of the seminiferous epithelium near the basement membrane towards Sertoli cells 
(Figs. 2b and 3b).  
Ultrastructurally, the vacuolated spaces observed in the region between the basement 
membrane and the basal epithelial layer revealed cytoplasmic contractions that shrink the 
intercellular spaces between Sertoli cell and the neighboring germ cells with formation of 
membrane-bounded vacuoles encircled by processes of Sertoli cells. The germinal epithelium rested 
on a basement membrane with an irregular arrangement (Fig. 3b). Moreover, the degeneration of 
the superficial layer characterized by cells fragmentation and anucleation was also evident. 
Spermatids appeared swollen, filled with vacuoles containing cellular debris that pushed the 
eccentrically placed nuclei, indicating a vacuolar degeneration of these germ cells. Retained and 
altered spermatids with nuclear vacuoles were identified in the basal compartment of the epithelium 
and embedded in Sertoli cells, that exhibited severe destruction and rarefaction of cytoplasm. No 
Sertoli cell and spermatid plasma membranes were visible, suggesting a possible phagocytic 
activity (Figs. 3 c-d).  
 
Epididymis morphological features 
In control group the epithelium of epidydimis consisted of tall columnar principal cells 
(PC), that exhibited a highly developed secretory and endocytic apparatus, and basally aligned 
nuclei. Stereocilia were abundant and the epididymal ducts appeared filled with spermatozoa (Figs. 
2 c-e). PC showed apical cytoplasmic protrusions referred to apical blebs that originated by apocrin 
secretion. Ultrastructurally, the apical blebs were found along the entire epididymis and they were 
characterized by heterogeneous shape and size at the apical surface of PC. These protrusions were 
directed towards the luminal compartment and contained several types of organelles, embedded in a 
homogeneous matrix. The blebs detached from the PC and entering the lumen, showed 
fragmentation and formation of aposomes, spherical membrane-bound bodies, closely related to 
spermatozoa. Aposomes contained electron dense particles and heterogeneous membrane-bounded 
vesicles, termed epididymosomes, that gave them different grades of electron density (Figs. 3 e-f)
25-
26
. 
As in control tissues, in animals belonging to group P the ultrastructural features of the 
lining epithelium revealed well developed secretory cells, with no apparent morphological 
differences. However, the most striking feature observed in treated group was related to the 
intraluminal compartment, where the spermatozoa number decreased significantly, up to disappear, 
and this reduction was accompanied by an increased presence of cellular debris (Fig. 2). Under 
TEM observation, the apocrin protrusions consisted of membrane-bound balloons containing a 
proteinaceous material and blebbing at the apical pole of secretory cells (Figs. 3 g-h). 
 
Morphometric Analysis  
Morphometric analyses on light microscopy showed an increase (p<0.05) of the area 
occupied by the seminiferous tubules in group P compared to controls (80.9±2.2 vs. 75.3±4.7 % of 
examined area). On the contrary, STED and SHE did not vary significantly between the groups 
(respectively, P vs K, 253.9±19.1 vs. 250.2±16.5 µm and 72.0±5.9 vs. 73.4±8.3 µm). Neither the 
epithelial height of epididymal ducti varied significantly between the groups (P vs. K 80.1±19.1 vs. 
88.6±11.3µm).  
The mean number of Sertoli cells, spermatogonia, spermatocytes, mature and immature 
spermatids per tubule section did not vary between the groups; group P showed a greater number of 
immature spermatozoa compared to controls (p<0.05) (Fig. 4).  
 
Evaluation and quantification of cell proliferation and apoptosis 
Immunohistochemical staining for Ki67 antigen did not reveal any significant difference 
between groups P and K, even if the percentage of the positive nuclear area was higher in control 
group than in PDN treated animals (2.105 ± 0.89 % vs. 1.525 ± 0.88 %). 
TUNEL assay did not reveal appreciable amounts of apoptotic cells, neither in group K nor 
in group P. 
 
Relative gene expression of STK11 in testis 
Administration of PDN induced a down-regulation (p<0.01) of the STK11 gene in testis by 
1.87-fold in group P compared to control group. Normalized fold expression (2
-Cq
) for P group 
was 0.534±0.170. 
 
Microarray data analysis 
After data extraction, normalization, and filtering, microarray data between group P and 
group K were compared for all the biological matrices under investigation. In skeletal muscle and 
testis, t-test statistics evidenced a total of 133 genes differentially expressed. Considering PBMCs,  
907 genes were differentially expressed at T3 and 1,416 T4 (Table 1).  
The functional analyses were performed on the DEG lists obtained for all the comparisons. 
In testis, analysis of gene function using Functional Annotation tool in DAVID did not reveal 
specific pathways significantly enriched in testis samples from PDN-treated animals. Nevertheless, 
DEG were found to be variously involved in the olfactory transduction (6 genes), as well as 
regulators of calcium homeostasis (6 genes), xenobiotic metabolism (5 genes), immune system 
regulation (12 genes), and apoptosis and cell cycle regulation (8 genes) (Table 2). The functional 
analysis of the DEG in skeletal muscle samples revealed a weak regulation of  single unrelated 
genes at the most (Table 3).On the other hand, enrichment analysis using the Functional Annotation 
tool in DAVID recognized several GO terms and KEGG pathways significantly enriched in PBMCs 
samples from both sampling times (Tables 4 and 5). 
A statistical approach for class prediction implemented in PAM software was applied to 
microarray expression data of all PBMCs samples (both sampling times, treated animals and 
controls) to evaluate the ability of sample classification. Firstly, a discriminant analysis was 
performed on selected samples (both controls and treated animals; Training Sample Set) to identify 
the smallest panel of genes which provided the smallest misclassification error. Cross-validation 
allows to evaluate the accuracy of class prediction on the Training Sample Set (10% of samples 
were randomly extracted and classification was based on the discriminant function calculated on the 
residual cases).PAM enabled to exactly discriminate the two classes (controls and treated animals) 
for 93% of samples using only 36 genes out of 17,157 (Fig. 5; Table 6). 
 
Discussion 
For many years several research groups have attempted to identify molecular markers useful 
to detect different anabolic treatments in cattle
27-31
. The usefulness of histological analyses on 
thymus morphology as a screening tool to identify illegal DEX treatments in cattle was already 
established
6-10
. On the contrary, gross and histopathological investigations on thymus were not 
useful to detect anabolic treatments with PDN in beef cattle
11
, and even gene expression profiling 
by DNA-microarray on thymus has revealed to be a weak tool
12
. In the same study, no PDN 
residues were found in the urine of treated animals, probably because of PDN rapid metabolism and 
excretion, and of the suspension of the treatment. Due to the scarce results obtained with thymus, 
the authors investigated on other biological matrices the potential alterations induced by PDN 
anabolic treatment, in order to identify and recognize potential biomarkers to be used for screening 
purpose. Reproductive tract, i.e. epididymis and testis, was analyzed to detect morphological and 
morphometric modifications. Moreover, transcriptomic signatures of PDN administration were 
investigated in PBMCs, skeletal muscle and testis.  
Testis relative weight did not vary between PDN treated animals and controls. Morphologic 
and ultrastructural appearance of testicular tissues was not exhaustive in identifying treatments, 
since the findings were very different from one animal to the other. Three cases were totally similar 
to animals of group K, whereas lesions heavily characterized the other treated animals, delineating a 
significant impact of treatment especially on spermatids. Morphometric analyses only revealed a 
significantly higher number of immature spermatozoa and an increase of the percentage of the area 
occupied by the seminiferous tubules in PDN treated beef calves compared to controls. Moreover, 
in the intraluminal compartment of epididymis, spermatozoa concentration decreased significantly 
up to disappear, whereas an increased presence of cellular debris was recorded. 
 The expression of STK11, also known as LKB1, in mammalian testis was demonstrated to 
be an essential regulator of spermatozoa release during spermiation
32
. This serine/threonine kinase 
is implicated in a number of key cellular processes. During the final phase of spermatogenesis, 
termed spermiation, mature spermatids detach from the supporting Sertoli cells and are released into 
the lumen of the seminiferous tubule. Denison et al.
32
  showed that spermiation is defective in the 
absence of LKB1. To the authors’ best knowledge this protein has never been investigated in bovine 
testis. The gene expression analysis showed in PDN treated animals a significant down-regulation 
for this gene. This data supports the hypothesis that the PDN treatment did not affect the production 
of mature spermatids, but it interfered with spermiation, probably involving STK11 pathway. The 
outcomes were represented by an apparently “healthy” morphology of testis, along with a huge 
decrease of spermatozoa in epididymis. These findings should be further investigated in order to 
verify if the association of morphometric analyses on testis and epididymis with STK11 expression 
could represent a useful marker for PDN treatment. 
Immunohistochemical staining for Ki67 antigen on testicular and epididymal tissues did not 
reveal a significant difference between group P and K, even if the percentage of the positive nuclear 
area was higher in K group. TUNEL assay did not reveal appreciable amounts of apoptotic cells, 
nor in group K and in group P. 
DNA microarray analysis identified a small set of differentially expressed genes between 
controls and PDN-treated animals in both testis and skeletal muscle samples.  
In testis samples, apoptosis pathway and/or cell cycle regulation seemed to be affected by 
the treatment even if the weak differences observed could not explain the histological findings of 
testis samples. However, up-regulation of tumour necrosis factor receptor superfamily member 10A 
(TNFRSF10A) was observed. This receptor is activated by tumour necrosis factor-related apoptosis 
inducing ligand (TNFSF10/TRAIL), inducing cell apoptosis. Testicular germ cells, and specifically 
spermatocytes, were shown to be sensitive to TRAIL-mediated apoptosis. In reproductive tissues, a 
well-characterized apoptotic pathway involves the signal transduction pathway of Fas
33
, a receptor 
which induces apoptosis after binding its ligand (FasL, up-regulated in PDN-treated animals) 
through an autocrine/paracrine signaling pathway
34
.  
Interestingly, olfactory transduction pathway was also regulated with 6 differentially 
expressed genes (Table 2). Surprisingly, a high number of olfactory receptors (ORs) expressed 
genes was found in the human testis and OR genes were shown to be more highly expressed in 
testis than in any other tissue
35
. A putative role for some members of this family in regulation of 
sperm motility was evidenced. In particular, various bioassays evidenced that the activation of 
hOR17-4 and mOR23 in human and mouse sperm, respectively, mediated flagellar motion patterns 
and chemotactic behavior 
36
.  
Regulation of genes involved in the xenobiotic metabolism was observed as well. In 
particular, some cytochrome P450 (CYP) isoforms (CYP11B2, CYP4F2, and CYP24A1) and one 
phase II enzyme (sulfotransferase family, cytosolic, 1C, member 2, SULT1C2) were up-regulated 
after the PDN treatment. Glucocorticoids play an important role in the control of Leydig cell 
function, but they have been associated to an impairment of the steroidogenic pathway, when in 
excess (even following DEX administration)
 37
. Testis expresses many drug-metabolizing enzymes, 
whose various physiological functions are not definitely known. Some isoforms are involved in 
xenobiotic drug metabolism, thereby probably determining testicular toxicity
38
. In cattle testis the 
administration of DEX alone or in combination with 17beta-oestradiol regulated the expression of 
some CYP isoforms (i.e. CYP1A1, CYP2E1, CYP17A1) and related transcription factors(e.g. 
peroxisome proliferator-activated receptor alpha)
39-40
, suggesting the potential usefulness of testis in 
the screening of drugs abuse in livestock farming.  
Very poor information could be extrapolated from microarray results in skeletal muscle 
tissue, apart from the confirmation of a putative bias towards cell differentiation rather than 
proliferation which was already showed for other anabolic growth promoter treatments
41-42
. The 
PDN treatment seemed indeed to affect single unrelated genes in bovine muscle rather to regulate 
more complex pathways or processes. 
The analysis of the microarray data relative to the bovine PBMCs collected at different 
sampling times revealed instead more interesting information. In particular, cytokine-cytokine 
receptor interaction pathway was significantly enriched at both sampling times with 18 and 20 
genes differentially expressed at T3 and T4, respectively. The analysis of the regulated cytokines 
seemed to suggest that the PDN treatment produced a more polarized response of Th2 at T3, e.g. 
IL4-receptor (IL4R), IL10R-alpha, IL2RG, transforming growth- factor beta 1, IL1R antagonist 
were over-expressed, and gamma interferon was down-regulated. On the other hand, at T4 no 
marked shift towards a specific T-helper sub-population seemed to occur, e.g.IL6R, IL15 and IL7 
were over-expressed and gamma interferon receptor alpha 2 and IL2 were down-regulated. IL2 
receptor signaling regulates tolerance and immunity. IL2 contributes to T-cell dependent activity, 
influencing CD8+ T cells activity, terminal differentiation of effector cells in primary response, and 
memory recall responses. IL2 is also the major cytokine contributing to the homeostasis of 
peripheral Treg cells: It is linked to Treg cells fitness maintaining both homeostasis and the 
suppressive program through induction of signal transducer and activator of transcription 5 
(STAT5; STAT5B was up-regulated in PBMCs at T3), which directly contributes to forkhead box 
P3 transcription
43
. In addition, it is known that glucorticoid receptor associates with several  
transcription factor  complexes which are regulated by signal transduction, such as STAT5
44
. Up-
regulation of IL2RG, STAT5B and many Th2 cytokines seemed to suggest a putative shift towards 
immune tolerance and anti-inflammatory pathways at T3. This is consistent with evidences 
indicating that glucocorticoids may cause a selective suppression of the Th1 immune response (e.g 
interferon gamma), and a Th2 shift, rather than generalized immunosuppression
45
. At T4 the 
scenery appeared to be more complex: overall, less cytokines were regulated respect to T3, 
probably due to the 6 days suspension of the treatment, and some of them showed a double effect 
acting as pro- or anti-inflammatory depending on the context (e.g. IL6, whose receptor was up-
regulated
46
). However, most of them seemed to be important for T and NK cell survival, 
development and homeostasis
47-48
. Interestingly, microarray analyses evidenced IL7 receptor alpha 
as a glucorticoid-inducible gene associated with enhanced IL-7 mediated signaling and function
49
. 
Toll-like receptor (TLR) pathway (11 genes) and MAPKK pathway (22 genes) were regulated at T4 
as well, thereby confirming a PDN effect on innate components of immunity
12
. Indeed, 
glucocorticoids were shown to regulate the expression of TLRs (e.g. TLR2, TLR3 and TLR4) in 
immune cells thereby affecting inflammation and host defense mechanisms
50
. Many genes 
implicated in transcription regulation are also altered by PDN treatment at both sampling times, 
most of which are involved in the control of PBMCs proliferation and/or differentiation (e.g., bone 
morphogenic protein 4, peroxisome proliferator-activated receptor-gamma, hypoxia-inducible 
factor 1-alpha, activin A receptor type 1). For instance, the up-regulation of peroxisome 
proliferator-activated receptor-gamma observed at T3, may support for the inhibition of cytokines 
that are important for Th1-cell differentiation
51
. Apart from confirming the effects on PDN on the 
maintenance of immunologic homeostasis, differentiation of T-lymphocytes population and its 
effect on both innate and adaptive arms of immune system
11
, what emerged from our investigation 
is that despite a mild effect obtained by PDN treatment on bovine thymus, PBMCs showed a more 
pronounced responsiveness against the treatment. This clear corticosteroid signature could allow to 
propose this matrix as an useful tool to identify animals potentially treated with PDN. In particular, 
the application of bioinformatics tools as PAM allowed to correctly discriminate 93% of samples 
using only 36 predictive genes that could be proposed as potential biomarkers not only during the 
illicit treatment with PDN but also after 6 days suspension. 
PDN and its metabolites are no longer detectable by LC-MS/MS methods in biological 
fluids. Moreover, they do not induce any histological alterations in thymus, differently from DEX 
treatments
11
. The present study confirmed the usefulness of an integrated approach to the 
investigation of PDN abuse in beef cattle, as previously reported
12,52
. Concerning indirect 
biomarkers, blood chemistry analysis and histological techniques have been proposed and adopted 
as alternative screening methods for the prevention of CSs abuse. Recent studies revealed the 
feasibility of transcriptome analysis using DNA-microarrays as a screening tool to identify the 
biological response to different illegal drugs, and could be useful to flank the official methods in 
detecting the use of anabolic compounds in beef cattle
12,52-55
.  
Histological investigations on epididymal tissues could represent a promising marker for 
PDN treatment in beef cattle. This simple and cheap analysis, in association with transcriptomic 
approach and TEM observation, could be used as a screening method in order to identify animals 
worthy of further investigation with official methods. Moreover, PBMCs markers suggested in this 
work could be very useful to monitor the illicit treatment in livestock. 
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Figure legends 
 
Fig. 1. Protocol of PDN treatment and PBMCs collection times. Beef calves were assigned to two 
experimental groups: Group P was administered prednisolone acetate (PA, Novosterol, Ceva Vetem 
spa, Italy) 30 mg day−1 per os for 35 days; Group K represented the control group. Six days after 
drug withdrawal the animals were slaughtered.   
 
Fig. 2. Semithin sections of testis and epididymis stained with toluidine blue (a, c, e: controls; b, d, 
f: treated). a, b testis samples; c-f epididymis samples. 
 a, c, e: Control animal: normal testis and epididymis with luminal spermatozoa scattered amongst 
the aposomes. 
 b, d, f:  PDN treated animal: prominent vacuolization of the seminiferous epithelium near the 
basement membrane. In epididymis spermatozoa concentration decreased significantly up to 
disappear, and this reduction was accompanied by an increased presence of cellular debris  (bar 10 
µm). Bm=Basement membrane.  
 
Fig. 3 Transmission electron micrographs of:  
a-d: Treated animal germinal epithelium: cytoplasmic shrinkage, extensive round spermatid 
exfoliation and atypical residual bodies in the luminal surface (rb). Degenerative changes in round 
and elongated spermatids (arrows) (–a: bar 10µm; b, c: bar 5 µm). 
e-f: Epithelium of epidydimis in control animals: aposomes (AP) found in the epididymal lumen 
anchoring the sperm nucleus (e: bar 5 µm). Epididymosomes represented by a heterogeneous 
variety of vesicles (asterisk) (f: bar 1 µm). 
g-h: Treated animal epididymis: columnar epithelial cells showing microvilli (mv) and apical blebs 
(ab) (g: bar 5 µm). Ultrastructure of an aposome (AP) anchored to an immature sperm cell with 
swelling of sperm head plasma membrane (asterisk) (h: bar 5 µm). Basement membrane (Bm), 
spermatogonia (Sg), Sertoli cell (Sc), spermatocytes (Sp), elongated spermatides (eS), round 
spermatides (rS) and residual bodies (rb). 
 
Fig. 4. Graphic representation of the distribution of the mean number of Sertoli cells, immature 
spermatozoa, round and elongated spermatids, spermatocytes, and spermatogonia per tubule section 
(P = prednisolone; K = control; *p<0.05) 
 
Fig. 5. Plot of cross-validated probabilities for sample classification using DEG (t-test). On x-axis 
individual samples: 1–14 negative controls (K), 15–30 PDN-treated animals (P); on y-axis the 
probability of being classified as controls (diamonds) or treated (squares); training error 0.03.  
  
Table 1 
DEG obtained from t-test analysis of testis, skeletal muscle and PBMCs samples  
 Skeletal muscle Testis PBMCs (T3) PBMCs (T4) 
Up-regulated 64 84 539 768 
Down-regulated 69 49 368 648 
p<0.05, FC≥1.5 
  
Table 2  
DEG obtained from t-test analysis of testis samples from bovine treated with PDN. 
Identifier Gene FC 
 Olfactory transduction  
XM_593044 Olfactory receptor 6B2 (LOC515090) -1.6 
XM_591408 Olfactory receptor, family 52, subfamily M, member 1 (OR52M1) 1.9 
XM_864501 Olfactory receptor, family 6, subfamily C, member 75 (OR6C75) 1.8 
XM_582572 Olfactory receptor, family 2, subfamily AG, member 1 (OR2AG1) 1.6 
AF074014 Cyclic nucleotide-gated cation channel beta-1 isoform c (CNGB1) 1.6 
XM_003584236 Olfactory receptor 8G1-like (LOC616755) 1.5 
 Calcium homeostasis  
NM_001192710 Cholinergic receptor, nicotinic, alpha 2 (neuronal) (CHRNA2) 2.3 
NM_173954 Parathyroid hormone (PTH) 1.8 
U81159 Magnesium-dependent calcium inhibitable phosphatase (MCPP) 1.8 
XM_608438 Calcium channel, voltage-dependent, alpha 2/delta subunit 4 (CACNA2D4) 1.7 
NM_173957 Regucalcin (senescence marker protein-30) (RGN) -1.6 
XM_614307 5-Hydroxytryptamine (serotonin) receptor 3B, ionotropic (HTR3B) 1.5 
 Xenobiotics metabolism  
NM_173993 Aryl hydrocarbon receptor nuclear translocator (ARNT) -1.5 
NM_174638 Cytochrome P450, subfamily XI B, polypeptide 1 (CYP11B2) 2.8 
XM_864665 Sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2) 1.7 
NM_001075322 Cytochrome P450, family 4, subfamily F, polypeptide 2 (CYP4F2) 1.5 
XM_591370 Cytochrome P450, family 24, subfamily A, polypeptide 1-like, transcript 
variant 2 (CYP24A1) 
1.5 
 
Immune system regulation  
XR_083623 Recombination activating gene 1 activating protein 1-like (LOC520463) 
miscRNA 
-4.1 
NM_001205850 Cytoplasmic FMR1 interacting protein 2 (CYFIP2) -3.1 
NM_001101251 Interferon, gamma-inducible protein 30 (IFI30) -1.5 
NM_001075142 Interleukin 4 receptor (IL4R) -1.5 
XM_003587343 Leukocyte immunoglobulin-like receptor subfamily A member 6-like 
(LOC790255) 
1.9 
XR_082749 Colony stimulating factor 3 receptor (CSF3R) 1.7 
NM_001105388 IL2-inducible T-cell kinase (ITK) 1.6 
XM_584848 Immunoglobin superfamily, member 21-like (IGSF21) 1.5 
NM_001045933 Forkhead box P3 (FOXP3) 1.5 
NM_001075291 Zinc finger CCCH-type containing 8 (ZC3H8) 1.5 
NM_001075807 CKLF-like MARVEL transmembrane domain containing 2 (CMTM2) 1.5 
XM_002699526 Interferon regulatory factor 2 binding protein 1 1.5 
 Apoptosis and cell cycle regulation  
NM_001205850 Cytoplasmic FMR1 interacting protein 2 (CYFIP2) -3.1 
NM_173957 Regucalcin (senescence marker protein-30) (RGN) -1.6 
BC149759 Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) 2.0 
NM_001192518 Unc-5 homolog D (C. elegans) (UNC5D) 1.9 
NM_001098859 Fas ligand (TNF superfamily, member 6) (FASLG) 1.5 
BM255900 Cyclin-dependent kinase 6 (CDK6) 1.5 
CB427007 Cyclin-T1 (CCNT1) 1.5 
NM_001046178 Protein phosphatase 1, regulatory subunit 15A (PPP1R15A) 1.5 
p<0.05, FC≥1.5 
  
Table 3 
DEG obtained from t-test analysis of skeletal muscle samples from bovine treated with PDN. 
Identifier Gene FC 
 Xenobiotic metabolism 
 
NM_001075823 Sulfotransferase family cytosolic 1B member 1 (SULT1B1) -2.1 
NM_174530 Cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1) 1.7 
 Cell cycle regulation   
NM_001076062 Cell cycle associated protein 1 (CAPRIN1) -1.5 
NM_001083449 Cell death-inducing DFFA-like effector a (CIDEA) 1.9 
NM_173954 Zygote arrest 1-like (ZAR1L) 1.8 
NM_001206050 Meteorin, glial cell differentiation regulator-like (METRNL) 1.7 
NM_001101183 Transforming growth factor, beta 3 (TGFB3) 1.5 
 Cytokine activity  
NM_174356 Interleukin 12B (IL12B) -1.5 
NM_174006 Chemokine (C-C motif) ligand 2 (CCL2) 3.9 
NM_174007 Chemokine (C-C motif) ligand 8 (CCL8) 2.2 
p<0.05, FC≥1.5 
Table 4.  
Biological processes, molecular functions and KEGG pathways significantly enriched in T3 
PBMCs from PDN group animals using the list of DEG (t-test). 
Category  Count PValue FE FDR 
GO_BP positive regulation of transcription, DNA-
dependent 
19 3E-04 3E+00 0.58 
GO_BP positive regulation of RNA metabolic 
process 
19 3E-04 3E+00 0.58 
GO_BP positive regulation of transcription 21 5E-04 2E+00 0.81 
GO_BP positive regulation of macromolecule 
metabolic process 
26 8E-04 2E+00 1.38 
GO_BP positive regulation of gene expression 21 8E-04 2E+00 1.39 
GO_BP regulation of transcription from RNA 
polymerase II promoter 
22 1E-03 2E+00 1.77 
GO_BP positive regulation of transcription from 
RNA polymerase II promoter 
16 1E-03 3E+00 1.84 
GO_BP positive regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 
21 1E-03 2E+00 2.46 
GO_BP positive regulation of macromolecule 
biosynthetic process 
22 2E-03 2E+00 2.88 
GO_BP regulation of transcription, DNA-dependent 43 2E-03 2E+00 3.28 
GO_BP positive regulation of nitrogen compound 
metabolic process 
21 2E-03 2E+00 3.50 
GO_BP positive regulation of cellular biosynthetic 22 3E-03 2E+00 4.41 
process 
GO_BP regulation of RNA metabolic process 43 3E-03 2E+00 5.01 
GO_BP positive regulation of biosynthetic process 22 3E-03 2E+00 5.15 
GO_BP heart development 11 6E-03 3E+00 9.32 
GO_BP negative regulation of cell proliferation 12 7E-03 3E+00 11.59 
GO_BP regulation of transcription 53 1E-02 1E+00 16.02 
GO_BP positive regulation of cell differentiation 10 1E-02 3E+00 17.51 
GO_BP regulation of cell proliferation 20 2E-02 2E+00 25.21 
GO_BP regulation of growth 12 2E-02 2E+00 26.01 
GO_BP BMP signaling pathway 4 2E-02 7E+00 26.04 
GO_BP positive regulation of developmental 
process 
11 2E-02 2E+00 27.98 
GO_BP transmembrane receptor protein 
serine/threonine kinase signaling pathway 
6 2E-02 4E+00 28.66 
GO_BP placenta development 5 3E-02 4E+00 36.29 
GO_BP tRNA modification 4 3E-02 6E+00 37.31 
GO_BP fat cell differentiation 5 3E-02 4E+00 40.42 
GO_BP pattern specification process 9 4E-02 2E+00 46.01 
GO_BP tRNA processing 6 5E-02 3E+00 54.72 
GO_MF cytokine binding 12 4E-05 5E+00 0.06 
GO_MF sequence-specific DNA binding 24 3E-04 2E+00 0.50 
GO_MF transcription factor activity 29 6E-04 2E+00 0.89 
GO_MF transcription regulator activity 41 8E-04 2E+00 1.09 
GO_MF cytokine receptor activity 6 7E-03 5E+00 9.36 
GO_MF C-C chemokine binding 5 7E-03 6E+00 10.03 
GO_MF C-C chemokine receptor activity 5 7E-03 6E+00 10.03 
GO_MF chemokine receptor activity 5 1E-02 5E+00 17.53 
GO_MF chemokine binding 5 2E-02 5E+00 23.73 
GO_MF protein dimerization activity 15 3E-02 2E+00 38.01 
GO_MF DNA binding 45 4E-02 1E+00 44.04 
KEGG Cytokine-cytokine receptor interaction 18 2E-04 3E+00 0.24 
KEGG Systemic lupus erythematosus 11 4E-04 4E+00 0.52 
KEGG Chemokine signaling pathway 12 4E-02 2E+00 39.63 
GO: Gene Ontology; BP: Biological Processes; MF: Molecular Functions; KEGG: KEGG 
pathways; FE: Fold Enrichment; FDR: False Discovery Rate 
  
Table 5.  
Biological processes, molecular functions and KEGG pathways significantly enriched in T4 
PBMCs from PDN group animals using the list of DEG (t-test). 
Category  Count PValue FE FDR 
 
GO_BP 
 
regulation of transcription, DNA-dependent 
 
56 
 
0.004 
 
1.439 
 
7.2 
GO_BP regulation of phosphorylation 20 0.004 2.009 7.3 
GO_BP regulation of transcription 74 0.006 1.339 9.3 
GO_BP regulation of phosphorus metabolic process 20 0.006 1.940 10.5 
GO_BP regulation of phosphate metabolic process 20 0.006 1.940 10.5 
GO_BP regulation of RNA metabolic process 56 0.007 1.406 11.2 
GO_BP regulation of protein kinase activity 14 0.008 2.243 13.4 
GO_BP regulation of transferase activity 15 0.009 2.161 13.5 
GO_BP cell activation 15 0.009 2.161 13.5 
GO_BP positive regulation of transferase activity 11 0.009 2.572 14.3 
GO_BP positive regulation of protein kinase activity 10 0.012 2.641 18.1 
GO_BP regulation of kinase activity 14 0.014 2.102 21.8 
GO_BP cell cycle 25 0.015 1.658 22.2 
GO_BP positive regulation of kinase activity 10 0.016 2.502 24.5 
GO_BP ribonucleoside monophosphate biosynthetic 
process 
5 0.022 4.457 31.4 
GO_BP leukocyte activation 13 0.022 2.060 31.6 
GO_BP regulation of MAP kinase activity 8 0.025 2.716 34.9 
GO_BP transcription 38 0.026 1.415 35.9 
GO_BP ribonucleoside monophosphate metabolic 5 0.033 3.961 43.4 
process 
GO_BP protein kinase cascade 12 0.036 1.990 46.6 
GO_BP positive regulation of MAP kinase activity 6 0.037 3.169 47.1 
GO_BP MAPKKK cascade 8 0.043 2.427 52.7 
GO_BP ribosome biogenesis 9 0.043 2.252 52.8 
GO_MF phosphoinositide binding 10 3E-04 4E+00 4E-01 
GO_MF phospholipid binding 13 1E-03 3E+00 2E+00 
GO_MF heparin binding 7 1E-02 4E+00 1E+01 
GO_MF N-methyltransferase activity 6 2E-02 4E+00 2E+01 
GO_MF sequence-specific DNA binding 25 2E-02 2E+00 2E+01 
GO_MF transcription regulator activity 47 3E-02 1E+00 3E+01 
GO_MF glycosaminoglycan binding 8 3E-02 3E+00 4E+01 
GO_MF peptide receptor activity 10 3E-02 2E+00 4E+01 
GO_MF peptide receptor activity, G-protein coupled 10 3E-02 2E+00 4E+01 
GO_MF GTPase activity 10 4E-02 2E+00 4E+01 
GO_MF chemokine receptor activity 5 4E-02 4E+00 5E+01 
GO_MF low-density lipoprotein binding 4 5E-02 5E+00 5E+01 
KEGG Intestinal immune network for IgA production 9 0.002 3.637 2.9 
KEGG Cytokine-cytokine receptor interaction 20 0.005 1.966 6.0 
KEGG Toll-like receptor signaling pathway 11 0.028 2.163 28.5 
KEGG MAPK signaling pathway 22 0.030 1.600 30.6 
GO: Gene Ontology; BP: Biological Processes; MF: Molecular Functions; KEGG: KEGG 
pathways; FE: Fold Enrichment; FDR: False Discovery Rate 
  
Table 6 
Most predictive genes identified by PAM software. 
ProbeID GenBank 
Accession 
GeneSymbol Description 
A_73_100298 NM_001102271 CLK1 Bos taurus CDC-like kinase 1 (CLK1) 
A_73_100941 XM_015475453 FBRSL1 Bos taurus fibrosin-like1 
A_73_100990 NM_001037616 HMGB2 Bos taurus high mobility group box 2 
A_73_101271 NM_001114192 HSPA4 Bos taurus heat shock 70kDa protein 4 
A_73_101276 NM_001080730 MRPL39 Bos taurus mitochondrial ribosomal protein L39 
A_73_103257 NM_001192222 THUMPD2 Bos taurus THUMP domain containing 2 
A_73_103288 BM087726 - Rep: Pistil extensin like protein - Nicotiana 
tabacum (Common tobacco), partial (6%) 
A_73_103758 NM_001038074 COX4NB Bos taurus COX4 neighbor 
A_73_103832 NM_001045900 PSMD3 Bos taurus proteasome (prosome, macropain) 
26S subunit, non-ATPase, 3 
A_73_103999 BF041736 - Rep: 3-oxoacyl-acyl-carrier protein reductase - 
Plasmodium yoelii yoelii, partial (5%) 
A_73_104896 DV786218 - HW_Liver_4_D04 Bos taurus CF-24-HW liver 
cDNA library Bos taurus cDNA 
A_73_105049 NM_001035389 ING4 Bos taurus inhibitor of growth family, member 4 
A_73_105411 NM_001191328 TSSC1 Bos taurus tumor suppressing subtransferable 
candidate 1 
A_73_106645 NM_001098863 MSMO1 Bos taurus methylsterol monooxygenase 1 
A_73_107442 XM_001790523 EXOSC5 Bos taurus exosome component 
A_73_108504 NM_001206196 KLHL24 Bos taurus kelch-like 24 (Drosophila) 
A_73_110210 XM_001787300 CABLES1 Bos taurus Cdk5 and Abl enzyme substrate 1 
A_73_112712 NM_001046136 ABCF2 Bos taurus ATP-binding cassette, sub-family F, 
member 2 
A_73_113837 NM_001101131 MAT2A Bos taurus methionine adenosyltransferase II, 
alpha 
A_73_114350 XM_002705068 AKNA Bos taurus AT-hook transcription factor 
A_73_115182 NM_001035358 MKNK1 Bos taurus MAP kinase interacting 
serine/threonine kinase 1 
A_73_115262 NM_001038088 NASP Bos taurus nuclear autoantigenic sperm protein 
(histone-binding) 
A_73_115371 XM_870542 GRK6 Bos taurus similar to G protein-coupled receptor 
kinase 6 
A_73_115718 NM_001191138 ELF2 Bos taurus E74-like factor 2 
A_73_116099 NM_178317 TRIB2 Bos taurus tribbles homolog 2 (Drosophila) 
A_73_116856 XM_001788896 GPCPD1 Bos taurus glycerophosphocholine 
phosphodiesterase GDE1 homolog (S. 
cerevisiae) 
A_73_117218 XM_867197 FCHSD2 Bos taurus FCH and double SH3 domains 2, 
transcript variant X1 
A_73_117533 NM_174759 PDCL Bos taurus phosducin-like 
A_73_117749 NM_001083515 TMEM87A Bos taurus transmembrane protein 87A 
A_73_117986 NM_001076257 ARRDC3 Bos taurus arrestin domain containing 3 
A_73_119285 NM_001075217 SIRT7 Bos taurus sirtuin 7 
A_73_119510 NM_001075558 HERPUD2 Bos taurus HERPUD family member 2 
A_73_119516 NM_001206899 MNT Bos taurus MAX binding protein 
A_73_119519 CN442042 - BE04028A1A06 Normalized and Subtracted 
bovine embryonic and extraembryonic tissue 
Bos taurus cDNA clone BE04028A1A06 5 
A_73_120487 NM_001045866 BRD2 Bos taurus bromodomain containing 2 
A_73_121009 NM_001099065 C16H1orf55 Bos taurus chromosome 16 open reading frame, 
human C1orf55 
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